Scholar Rock Holding Corp (SRRK) SEC Filings, Mar-Apr 2026

Scholar Rock Holding Corporation is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders on June 4, 2026 at 12:00 p.m. Eastern Time. Stockholders will elect four Class II directors to serve until 2029, ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, and cast a non-binding advisory vote on executive compensation.

The meeting will be held entirely online via a secure webcast, with voting available by internet, telephone, mail, QR code, or during the meeting using a 16-digit control number. The record date is April 10, 2026, when 119,301,886 shares of common stock were outstanding and entitled to one vote each. The Board recommends voting FOR all three proposals and outlines detailed governance practices, director biographies, committee structures, and director pay, including cash retainers and annual equity grants.

Scholar Rock Holding Corp Chief Operating Officer Keith Woods completed a mandated sale of 10,220 shares of common stock at $49.5745 per share. The sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units on April 15, 2026 and was not a discretionary trade.

After this transaction, Woods directly holds 620,055 shares. His equity position also includes 122,021 restricted stock units subject to time-based vesting and 450,000 restricted stock units subject to performance- and time-based vesting, aligning his compensation with future company performance and continued service.

Scholar Rock Holding Corp director and President of R&D Akshay Vaishnaw sold 12,246 shares of common stock in an open-market transaction at $49.5745 per share. According to the disclosure, this sale was mandated solely to cover tax withholding on restricted stock units that vested on April 15, 2026, and was executed as a required “sell to cover” transaction rather than a discretionary trade. After the sale, Vaishnaw directly holds 630,542 shares, along with vested and unvested RSU awards that continue to vest over four years, subject to ongoing service.

Scholar Rock Holding Corp's Chief Financial Officer Vikas Sinha reported an open-market sale of 10,410 shares of common stock at an average price of $49.5745 per share on April 16, 2026. According to the footnotes, this sale was required solely to cover tax withholding obligations tied to restricted stock units that vested on April 15, 2026, under the company’s equity incentive plans and was not a discretionary trade.

After this transaction, Sinha’s reported equity position totals 619,856 equity-linked interests, consisting of 47,835 shares of common stock, 122,021 time-based RSUs, and 450,000 RSUs subject to performance- and time-based vesting conditions. The RSU awards referenced in the transaction were granted on April 27, 2025 and vest annually over four years, contingent on continued service.

Scholar Rock Holding Corp's CEO David Hallal reported a tax-driven share sale tied to equity compensation. On April 15, 2026, restricted stock units vested, and 30,615 shares of common stock were sold at an average price of $49.5745 per share to cover related tax withholding obligations. The filing states this mandatory "sell to cover" transaction was executed through a designated brokerage firm and was not a discretionary trade by Hallal. After the sale, he directly held 1,639,034 shares of common stock. He also has additional exposure through 198,530 shares of common stock, 315,504 time-based RSUs, and 1,125,000 performance- and time-based RSUs, plus indirect holdings in the Hallal Family Irrevocable Trust, for which he disclaims full beneficial ownership.

Mohammed Qatanani filed a Form 144 notice to sell 23,408 shares of Common Stock on 04/06/2026 via a stock option exercise for cash. The filing lists three prior sales in the past three months: 13,112 shares on 01/14/2026, 14,898 shares on 01/22/2026, and 8,484 shares on 02/23/2026.

Scholar Rock Holding Corporation filed a current report describing that it has resubmitted its Biologics License Application (BLA) to the FDA for apitegromab, a muscle-targeted therapy for children and adults with spinal muscular atrophy (SMA).

The company anticipates FDA acceptance of the resubmitted BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026. The resubmission also adds a second U.S. fill-finish facility alongside Catalent Indiana to support the apitegromab supply chain and planned global commercial demand. In Europe, the EMA review of the apitegromab Marketing Authorisation Application is progressing, with a decision anticipated around mid-2026.

Scholar Rock Holding Corp — an amended Schedule 13G/A shows The Vanguard Group reporting 0 shares beneficially owned of common stock following an internal realignment. The filing explains that on January 12, 2026 Vanguard disaggregated certain subsidiaries under SEC Release No. 34-39538, and the amendment is signed 03/27/2026.

Scholar Rock Holding Corporation filed an amended report to correct a scrivener’s error in its prior earnings release, updating net loss per share and weighted average shares outstanding for the quarter ended December 31, 2025.

For that quarter, the company reported a net loss of $91.0 million, or $0.76 per share, compared with a net loss of $66.5 million, or $0.61 per share, a year earlier. For full year 2025, net loss was $377.9 million, or $3.29 per share, versus $246.3 million, or $2.47 per share, in 2024. Scholar Rock highlighted progress on apitegromab for spinal muscular atrophy, noting it is ready to resubmit its BLA after FDA reinspection of Novo Nordisk’s Catalent Indiana facility, and described a new multi‑tranche financing with Blue Owl Capital, including an initial $100 million used to retire its prior Oxford Finance debt and additional tranches tied to future milestones and approvals.